Specialised nutrition in head and neck cancer surgery

Phase 1

Completed

• Conditions: Patients with cancer of the oral cavity, pharynx or larynx.; Cancer - Head and neck

• Registration Number: ACTRN12607000162415
• Lead Sponsor: Dr Mark Izzard

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-03-09
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Scheduled for radical resection of cancers of the oral cavity, pharynx and larynx.

Exclusion Criteria

Patients will be excluded if pregnant, diabetic, on immunosuppressants, have had previous wide-field radical radiotherapy for head and neck cancer, or have greater than 10% weight loss.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Postoperative immune and inflammatory status which includes C-reactive protein, total lymphocytes, CD3, CD4, CD8, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin (IgA), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).[Measured on postoperative days 1, 3, 5 and 7]

Secondary Outcome Measures

Name	Time	Method
Postoperative infectious complications [Over the first 30 postoperative days.];Change in total body protein [From baseline to postoperative day 10.]